Targeting the TGF-β1 Pathway to Prevent Normal Tissue Injury After Cancer Therapy
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
With >10,000,000 cancer survivors in the U.S. alone, the late effects of cancer treatment are a significant public health issue. Over the past 15 years, much work has been done that has led to an improvement in our understanding of the molecular mechanisms underlying the development of normal tissue injury after cancer therapy. In many cases, these injuries are characterized at the histologic level by loss of parenchymal cells, excessive fibrosis, and tissue atrophy. Among the many cytokines involved in this process, transforming growth factor (TGF)-β1 is thought to play a pivotal role. TGF-β1 has a multitude of functions, including both promoting the formation and inhibiting the breakdown of connective tissue. It also inhibits epithelial cell proliferation. TGF-β1 is overexpressed at sites of injury after radiation and chemotherapy. Thus, TGF-β1 represents a logical target for molecular therapies designed to prevent or reduce normal tissue injury after cancer therapy. Herein, the evidence supporting the critical role of TGF-ß1 in the development of normal tissue injury after cancer therapy is reviewed and the results of recent research aimed at preventing normal tissue injury by targeting the TGF-ß1 pathway are presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tolerance of normal tissue to therapeutic irradiation
Emami, B., Lyman, J., Brown, A., Cola, L., Goitein, M., Munzenrider, J. E., Shank, B., Solin, L. J., & Wesson, M. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90171-y · Cited by 4,488
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Transforming Growth Factor- β Activation in the Lung: Focus on Fibrosis and Reactive Oxygen Species
Koli, K., Myllärniemi, M., Keski-Oja, J., & Kinnula, V. L. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1914 · Cited by 168
Cited by
Ionizing Radiation: The Good, the Bad, and the Ugly
Ryan, J. L. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.411 · Cited by 502
Targeting TGFβ signal transduction for cancer therapy
Liu, S., Ren, J., & ten Dijke, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00436-9 · Cited by 413
“Therefore, the combination of anti-TGFβ therapy with radiotherapy may improve treatment by enhancing tumor cell radiosensitivity and protecting normal tissues.(266,267) In a phase 2 clinical trial, the TGFβ-blocking antibody fresolimumab (GC1008) was combined with focal irradiation for the treatment of metastatic brea…”
BackgroundConversion of Mechanical Force into TGF-β-Mediated Biochemical Signals
Maeda, T., Sakabe, T., Sunaga, A., Sakai, K., Rivera, A. L., Keene, D. R., Sasaki, T., Stavnezer, E., Iannotti, J., Schweitzer, R., et al. (2011) · Current Biology · doi:10.1016/j.cub.2011.04.007 · Cited by 366
Assessing the interactions between radiotherapy and antitumour immunity
Grassberger, C., Ellsworth, S. G., Wilks, M. Q., Keane, F. K., & Loeffler, J. S. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0238-9 · Cited by 244
Mohamed, H. A., & Said, R. S. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107347 · Cited by 60
Metadata
- Authors
- Anscher, M. S.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-03-16
- Volume
- 15
- Issue
- 4
- Pages
- 350-359
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2152645550
- Cited by
- 140
- References
- 5
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.